New Antiresorptive Therapies for Postmenopausal Osteoporosis
Journal of Menopausal Medicine
; : 1-11, 2015.
Article
en En
| WPRIM
| ID: wpr-174728
Biblioteca responsable:
WPRO
ABSTRACT
Osteoporosis is a systemic skeletal disease whose risk increases with age and it is common among postmenopausal women. Currently, almost all pharmacological agents for osteoporosis target the bone resorption component of bone remodeling activity. Current antiresorptive agents are effective, but the effectiveness of some agents is limited by real or perceived intolerance, longterm adverse events (AEs), coexisting comorbidities, and inadequate long-term adherence. New antiresorptive therapies that may expand options for the prevention and treatment of osteoporosis include denosumab, combination of conjugated estrogen/bazedoxifene and cathepsin K inhibitors. However, the long-term efficacy and AEs of these antiresorptive therapies need to be confirmed in studies with a longer follow-up period.
Palabras clave
Texto completo:
1
Base de datos:
WPRIM
Asunto principal:
Osteoporosis
/
Resorción Ósea
/
Comorbilidad
/
Osteoporosis Posmenopáusica
/
Remodelación Ósea
/
Posmenopausia
/
Conservadores de la Densidad Ósea
/
Catepsina K
/
Denosumab
Límite:
Female
/
Humans
Idioma:
En
Revista:
Journal of Menopausal Medicine
Año:
2015
Tipo del documento:
Article